Streetbeat News

Products Services

NKLA

Nikola Corporation (NASDAQ:NKLA) reported Q2 vehicle production and deliveries, with wholesale of 45 trucks and retail of 66 trucks. The company doubled its retail sales compared to Q1 and is planning to introduce a hydrogen fuel cell electric truck in Q3. Full financial results will be announced on August 4, 2023.

Portfolio Pulse from Happy Mohamed

July 05, 2023 | 12:05 pm

ABBV

JNJ

PTGX

Protagonist Therapeutics Inc (PTGX) announced positive results from the Phase 2b FRONTIER 1 trial of JNJ-2113, a psoriasis treatment developed by Janssen Biotech, a unit of Johnson & Johnson (JNJ). The drug hit its primary and secondary endpoints, showing significant improvements in skin lesions. However, it fell short of rival treatment Skyrizi, commercialized by AbbVie Inc (ABBV), in terms of PASI 90 score. PTGX shares are up 3.41% premarket.

Portfolio Pulse from Vandana Singh

July 05, 2023 | 11:33 am

CGTX

Cognition Therapeutics has announced the activation of the first clinical trial site for the Phase 2 START study of CT1812 in adults with early Alzheimer's disease. The site can now begin recruiting participants for the 540-patient study.

Portfolio Pulse from Benzinga Newsdesk

July 05, 2023 | 11:33 am

EWG

INTC

SOXX

Germany's Finance Minister Olaf Scholz has indicated that there are other chip projects in the works by German and other companies. The specific companies involved were not mentioned in the article.

Portfolio Pulse from Charles Gross

July 05, 2023 | 11:29 am

DXCM

DexCom, Inc.'s (NASDAQ:DXCM) Dexcom G7 Continuous Glucose Monitoring System has been approved by Health Canada. The device can warn of high or low glucose levels and help avoid hypoglycemic events. The approval gives Canadians access to a technology that reduces hospitalizations and emergency room visits due to hypoglycemia by up to 42%. The product is expected to be launched in Canada by the end of 2023.

Portfolio Pulse from Nabaparna Bhattacharya

July 05, 2023 | 11:16 am

TSLA

Tesla, Inc. (NASDAQ:TSLA) has reduced prices of its Model 3 and Y EVs in Japan by low single-digit percentages, continuing its aggressive pricing strategy into Q3. This follows Tesla's Q2 deliveries outperformance, partly attributed to price cuts and promotional measures. However, this move may stir investor anxiety concerning demand and margins ahead of the company’s earnings report due on July 19. In premarket trading, Tesla stock was down 0.60% at $278.14.

Portfolio Pulse from Shanthi Rexaline

July 05, 2023 | 11:15 am

CCCC

The FDA has cleared C4 Therapeutics' Investigational New Drug Application for CFT8919, a treatment for non-small cell lung cancer. C4T plans to initiate trials outside Greater China after Betta Pharmaceuticals concludes its Phase 1 dose escalation study in the region.

Portfolio Pulse from Benzinga Newsdesk

July 05, 2023 | 11:03 am

MRNA

Moderna, Inc. (NASDAQ:MRNA) has announced regulatory submissions for its Respiratory Syncytial Virus (RSV) vaccine, mRNA-1345, aimed at preventing RSV-associated lower respiratory tract disease and acute respiratory disease in adults aged 60 years or older. The company has submitted marketing authorization applications to the European Medicines Agency, Swissmedic, and the Therapeutic Goods Administration in Australia, and initiated the rolling submission process for a Biologics License Application to the U.S. FDA.

Portfolio Pulse from Benzinga Newsdesk

July 05, 2023 | 11:02 am

AMZN

Amazon.com Inc. has announced the Amazon Prime Day 2023 sale for July 11 and 12, offering discounts on a wide range of products. The company has provided tips on how to prepare for the sale, including becoming an Amazon Prime member, scoring free Amazon credit, updating payment methods, signing up for invite-only deals, and setting up deal alerts.

Portfolio Pulse from Rounak Jain

July 05, 2023 | 10:49 am

INCY

The Medicines and Healthcare Products Regulatory Agency has approved Incyte Biosciences' Opzelura (Ruxolitinib) cream for non-segmental vitiligo with facial involvement in patients aged 12 years and above.

Portfolio Pulse from Benzinga Newsdesk

July 05, 2023 | 10:16 am